LAVA Therapeutics N.V. (LVTX) DCF Valuation

LAVA Therapeutics N.V. (LVTX) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

LAVA Therapeutics N.V. (LVTX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of LAVA Therapeutics N.V.? Our LVTX DCF Calculator integrates real-world data with comprehensive customization features, enabling you to adjust forecasts and enhance your investment strategies.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 3.9 5.6 20.2 7.1 8.4 10.1 12.0 14.4 17.1
Revenue Growth, % 0 0 42.78 262.45 -65.09 19.42 19.42 19.42 19.42 19.42
EBITDA -9.9 -15.3 -42.8 -32.2 -42.2 -5.1 -6.0 -7.2 -8.6 -10.3
EBITDA, % 100 -391.04 -766.64 -159.23 -597.09 -60 -60 -60 -60 -60
Depreciation .1 .2 .3 .5 1.3 2.2 2.7 3.2 3.8 4.6
Depreciation, % 100 5.68 6.19 2.6 18.88 26.67 26.67 26.67 26.67 26.67
EBIT -10.0 -15.5 -43.1 -32.7 -43.5 -5.1 -6.0 -7.2 -8.6 -10.3
EBIT, % 100 -396.72 -772.82 -161.83 -615.97 -60 -60 -60 -60 -60
Total Cash 8.7 20.3 157.5 138.6 99.7 8.4 10.1 12.0 14.4 17.1
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .2 1.5 .8 3.4 1.8
Account Receivables, % 100 39.28 13.72 16.78 25.1
Inventories .0 1.0 -50.9 .0 .0 .4 .5 .6 .8 .9
Inventories, % 100 26.61 -912.65 0 0 5.32 5.32 5.32 5.32 5.32
Accounts Payable .4 1.0 2.7 4.1 4.6 4.4 5.2 6.2 7.4 8.9
Accounts Payable, % 100 24.93 47.72 20.45 65.68 51.76 51.76 51.76 51.76 51.76
Capital Expenditure -.9 -.7 -.9 -.6 -.8 -.8 -1.0 -1.1 -1.4 -1.6
Capital Expenditure, % 100 -17.59 -16.19 -3.03 -10.78 -9.52 -9.52 -9.52 -9.52 -9.52
Tax Rate, % -0.66914 -0.66914 -0.66914 -0.66914 -0.66914 -0.66914 -0.66914 -0.66914 -0.66914 -0.66914
EBITAT -10.0 -15.5 -43.3 -33.0 -43.8 -5.1 -6.0 -7.2 -8.6 -10.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -10.6 -17.8 10.6 -85.2 -41.1 -5.8 -4.2 -5.0 -6.0 -7.1
WACC, % 6.27 6.27 6.27 6.27 6.27 6.27 6.27 6.27 6.27 6.27
PV UFCF
SUM PV UFCF -23.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -7
Terminal Value -171
Present Terminal Value -126
Enterprise Value -149
Net Debt -40
Equity Value -110
Diluted Shares Outstanding, MM 27
Equity Value Per Share -4.11

What You Will Get

  • Real LAVA Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for LAVA Therapeutics N.V. (LVTX).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to suit your analysis.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on LAVA’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to LAVA Therapeutics N.V. (LVTX).
  • Time-Saving and Accurate: Skip building models from scratch while ensuring precision and flexibility in your assessments.

Key Features

  • Customizable Research Parameters: Adjust essential inputs such as clinical trial success rates, market penetration, and R&D expenditures.
  • Instant Valuation Metrics: Computes intrinsic value, net present value (NPV), and other key financial metrics in real-time.
  • Industry-Leading Precision: Leverages LAVA Therapeutics’ actual financial data for accurate valuation results.
  • Effortless Scenario Testing: Evaluate various assumptions and analyze different outcomes with ease.
  • Efficiency Booster: Streamline your analysis process without the need to create intricate valuation models from the ground up.

How It Works

  • Download: Obtain the pre-built Excel file containing LAVA Therapeutics N.V. (LVTX) financial data.
  • Customize: Modify projections, such as revenue growth, EBITDA %, and WACC as needed.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Develop various forecasts and assess outcomes immediately.
  • Make Decisions: Leverage the valuation findings to inform your investment approach.

Why Choose This Calculator for LAVA Therapeutics (LVTX)?

  • Accuracy: Utilizes real LAVA Therapeutics financial data to ensure precise calculations.
  • Flexibility: Allows users to easily test and adjust inputs as needed.
  • Time-Saving: Eliminates the need to create a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and detail expected by CFOs.
  • User-Friendly: Intuitive design makes it accessible for users with varying levels of financial modeling experience.

Who Should Use This Product?

  • Investors: Accurately assess LAVA Therapeutics N.V.'s (LVTX) fair value prior to making investment choices.
  • CFOs: Utilize a high-quality DCF model for financial reporting and strategic analysis.
  • Consultants: Easily customize the template for client valuation reports.
  • Entrepreneurs: Acquire insights into the financial modeling practices of leading biotech firms.
  • Educators: Employ it as a teaching resource to illustrate valuation techniques.

What the LAVA Template Contains

  • Preloaded LVTX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.